New targets for triple-negative breast cancer.Christina I. Herold, Carey K. Anders|PubMed|2013Cited by 29
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancerAna C. Garrido-Castro, Sara M. Tolaney, Lestat R. Ali et al.|Journal for ImmunoTherapy of Cancer|2025Cited by 15